Efficacy of Psychostimulant Drugs for Cocaine Dependence
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cocaine dependence is an increasingly prevalent disorder for which no medication is approved yet. Likewise opioid for heroin dependence, replacement therapy with psychostimulant could be efficacious for cocaine dependence. OBJECTIVES: To ascertain the efficacy of psychostimulants for cocaine dependence on cocaine use, sustained cocaine abstinence and retention in treatment. The influence of type of drug, comorbid disorders and clinical trial reporting quality over psychostimulants efficacy has also been studied. SEARCH STRATEGY: MEDLINE, EMBASE, PsycINFO, CENTRAL, references of obtained articles and experts in the field. SELECTION CRITERIA: Randomized parallel group controlled clinical trials comparing the efficacy of a psychostimulant against placebo have been included. DATA COLLECTION AND ANALYSIS: Two authors evaluated and extracted data. The Relative Risk (RR) was used to assess dichotomous outcomes except for adverse event (AE) induced dropouts for which the risk difference (RD) was preferred. The Standardized Mean Difference (SMD) was used to assess continuous outcomes. To determine the influence of moderating variables, a stratified analysis was conducted. Funnel plots were drawn to investigate the possibility of publication bias. MAIN RESULTS: Sixteen studies have been included, which have enrolled 1,345 patients. Seven drugs with psychostimulant effect or metabolized to a psychostimulant have been investigated: bupropion, dexamphetamine, methylphenidate, modafinil, mazindol, methamphetamine and selegiline. Psychostimulants did not reduce cocaine use (SMD 0.11, 95%CI: -0.07 to 0.29), showed a statistical trend over improving sustained cocaine abstinence (RR 1.41, 95%CI: 0.98 to 2.02, p=0.07) and did not improve retention in treatment (RR 0.97, 95%CI: 0.89 to 1.05). The proportion of AE induced dropouts was similar for psychostimulants and placebo (RD 0.01, 95%CI: -0.02 to 0.03). When the type of drug was included as a moderating variable, it was shown that the proportion of patients achieving sustained cocaine abstinence was higher with bupropion and dextroamphetamine, and also with modafinil, at a statistical trend of significance, than with placebo. Nevertheless, no studied drug was efficacious on any of the remaining outcomes. Besides, psychostimulants appeared to increase the proportion of patients achieving sustained cocaine and heroin abstinence amongst methadone maintained dual heroin-cocaine addicts. The main findings did not seem to be influenced by clinical trial reporting quality. No evidence of publication bias was found. AUTHORS' CONCLUSIONS: This review found mixed results, therefore evidence of the efficacy of psychostimulants for cocaine dependence is inconclusive. Nevertheless promising results exist for methadone maintained dual heroin-cocaine addicts and for some specific drugs such as dexamphetamine and bupropion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of drug dependence
Koob, G. F., & Bloom, F. E. (1988) · Science · doi:10.1126/science.2903550 · Cited by 2,070
Systematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
Dopamine in drug abuse and addiction: results from imaging studies and treatment implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., & Swanson, J. M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001507 · Cited by 1,101
Nicotine replacement therapy for smoking cessation
Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub2 · Cited by 972
Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects
Volkow, N. D., Wang, G.-J., Fowler, J. S., Logan, J., Gatley, S. J., Hitzemann, R., Chen, A. D., Dewey, S. L., & Pappas, N. (1997) · Nature · doi:10.1038/386830a0 · Cited by 854
Effects of chronic cocaine abuse on postsynaptic dopamine receptors
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.6.719 · Cited by 421
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391
Dwoskin, L. P., Rauhut, A. S., King‐Pospisil, K. A., & Bardo, M. T. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00178.x · Cited by 259
Schubiner, H., Downey, K. K., Arfken, C. L., Johanson, C.-E., Schuster, C. R., Lockhart, N., Edwards, A., Donlin, J., & Pihlgren, E. (2002) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.10.3.286 · Cited by 249
Cited by
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“Recently a Cochrane review has been published regarding efficacy of psychostimulant drugs for treatment of cocaine dependence (Castells et al., 2010) (Ia).”
BackgroundTreatment of substance abusing patients with comorbid psychiatric disorders
Kelly, T. M., Daley, D. C., & Douaihy, A. B. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.09.010 · Cited by 284
The effectiveness of compulsory drug treatment: A systematic review
Werb, D., Kamarulzaman, A., Meacham, M. C., Rafful, C., Fischer, B., Strathdee, S. A., & Wood, E. (2016) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.12.005 · Cited by 260
Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults
Castells, X., Blanco-Silvente, L., & Cunill, R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007813.pub3 · Cited by 209
Self-citationLevin, F. R., Mariani, J. J., Specker, S., Mooney, M., Mahony, A., Brooks, D. J., Babb, D., Bai, Y., Eberly, L. E., Nunes, E. V., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.41 · Cited by 179
Striatal ups and downs: Their roles in vulnerability to addictions in humans
Leyton, M., & Vezina, P. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.01.018 · Cited by 165
“Slow release DA indirect agonist preparations have shown modest, though inconsistent, efficacy in some populations (Castells et al., 2010; Mariani et al., 2012).”
Bentzley, B. S., Han, S. S., Neuner, S., Humphreys, K., Kampman, K. M., & Halpern, C. H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8049 · Cited by 161
Antipsychotic medications for cocaine dependence
Indave, B. I., Minozzi, S., Pani, P. P., & Amato, L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006306.pub3 · Cited by 122
Psychostimulant drugs for cocaine dependence
Castells, X., Cunill, R., Pérez-Mañá, C., Vidal, X., & Capellà, D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007380.pub4 · Cited by 110
Self-citationNuijten, M., Blanken, P., van de Wetering, B., Nuijen, B., van den Brink, W., & Hendriks, V. M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00205-1 · Cited by 87
Mariani, J. J., Pavlicova, M., Bisaga, A., Nunes, E. V., Brooks, D. J., & Levin, F. R. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.032 · Cited by 85
Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults
Castells, X., Ramos-Quiroga, J. A., Bosch, R., Nogueira, M., & Casas, M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007813.pub2 · Cited by 80
Self-citationBisagno, V., González, B., & Urbano, F. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.013 · Cited by 59
Bhatt, M., Zielinski, L., Baker-Beal, L., Bhatnagar, N., Mouravska, N., Laplante, P., Worster, A., Thabane, L., & Samaan, Z. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0370-x · Cited by 56
Levin, F. R., Mariani, J. J., Pavlicova, M., Choi, C. J., Mahony, A. L., Brooks, D. J., Bisaga, A., Dakwar, E., Carpenter, K. M., Naqvi, N., et al. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107700 · Cited by 54
“Amphetamine formulations have shown the most consistent positive therapeutic effects on cocaine use outcomes (Castells et al., 2010; Herin et al., 2010; Negus and Henningfield, 2015; Rush and Stoops, 2012).”
BackgroundNuijten, M., Blanken, P., van den Brink, W., & Hendriks, V. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.02.024 · Cited by 38
Pérez-Mañá, C., Castells, X., Vidal, X., Casas, M., & Capellà, D. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.08.012 · Cited by 33
Self-citationPsychosocial interventions for stimulant use disorder
Minozzi, S., Saulle, R., Amato, L., Traccis, F., & Agabio, R. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011866.pub3 · Cited by 32
Hamel, C., Corace, K., Hersi, M., Rice, D., Willows, M., Macpherson, P., Sproule, B., Flores-Aranda, J., Garber, G., Esmaeilisaraji, L., et al. (2020) · Systematic Reviews · doi:10.1186/s13643-020-01499-z · Cited by 17
Sepede, G., Di lorio, G., Lupi, M., Sarchione, F., Acciavatti, T., Fiori, F., Santacroce, R., Martinotti, G., Gambi, F., & Di Giannantonio, M. (2014) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000011 · Cited by 16
Cook, J., Lloyd-Jones, M., Arunogiri, S., Ogden, E., & Bonomo, Y. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867417714878 · Cited by 13
Metadata
- Authors
- Castells, X., Casas, M., Pérez-Mañá, C., Roncero, C., Vidal, X., & Capellà, D.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2010-02-17
- Issue
- 2
- Pages
- CD007380-CD007380
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W1921037097
- Cited by
- 130
- References
- 26
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.